Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study

Declaration of Competing Interest AG, AMM, ASSP, AXA, BFFR, CML, FCS, JFSF, LCLL, LRG, TBT, JICFN: declared no conflict of interest. ACMS, ALB, CAK, DDGH, EKEAL, EMR, MCSR, MK, RCFB: received funds or reimbursement from BioMarin Brasil Farmaceutica LTDA for attending related symposia, or speaker hon...

Descripción completa

Detalles Bibliográficos
Autores: Horovitz, Dafne Dain Gandelman, Leão, Emília Katiane Embiruçu de Araújo, Ribeiro, Erlane M., Martins, Ana M., Barth, Anneliese Lopes, Neri, João I. C. F., Kerstenetzky, Marcelo, Siqueira, Ana C. M., Ribeiro, Bethania F. R., Kim, Chong A., Santos, Francisca C., Franco, José F. S., Lichtvan, Leniza C. L., Giuliani, Liane R., Rodrigues, Maria do C. S., Bonatti, Renata C. F., Teixeira, Thaís B., Gonçalves, Alexandra, Lourenço, Charles M., Pereira, Ane S. S., Acosta, Angelina X.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Brasil
Institución:Fundação Oswaldo Cruz (FIOCRUZ)
Repositorio:Repositório Institucional da FIOCRUZ (ARCA)
Idioma:inglés
OAI Identifier:oai:arca.fiocruz.br:icict/46480
Acceso en línea:https://arca.fiocruz.br/handle/icict/46480
Access Level:acceso abierto
Palabra clave:Enzyme replacement therapy
Galsulfase
Long-term follow-up
Lysosomal storage disorder
MPS VI
Mucopolysaccharidosis VI
Maroteaux-Lamy Syndrome
Descripción
Sumario:Declaration of Competing Interest AG, AMM, ASSP, AXA, BFFR, CML, FCS, JFSF, LCLL, LRG, TBT, JICFN: declared no conflict of interest. ACMS, ALB, CAK, DDGH, EKEAL, EMR, MCSR, MK, RCFB: received funds or reimbursement from BioMarin Brasil Farmaceutica LTDA for attending related symposia, or speaker honoraria. DDGH: received consulting fees from BioMarin Brasil Farmaceutica LTDA.

Similares en LA Referencia